Subgloticc Secretion Drainage for Prevention of Vap Systematic Review
Subglottic secretion drainage for preventing ventilator-associated pneumonia: an overview of systematic reviews and an updated meta-analysis
Abstract
Although several guidelines recommend subglottic secretion drainage as a strategy for prevention of ventilator-associated pneumonia (VAP), its use is not widespread. With the aim to assess the effectiveness of subglottic secretion drainage for preventing VAP and to improve other outcomes such every bit mortality, duration of mechanical ventilation and length of stay in the intensive care unit (ICU) or hospital, an electronic search of the Cochrane Library, MEDLINE, Spider web of Science and Embase was undertaken. 9 systematic reviews with meta-analysis (in the overview of reviews) and 20 randomised controlled trials (in the updated meta-analysis) were included.
In the overview of reviews, all systematic reviews with meta-analysis included establish a positive consequence of subglottic secretion drainage in the reduction of incidence of VAP. In the updated meta-analysis, subglottic secretion drainage significantly reduced VAP incidence (risk ratio (RR) 0.56, 95% CI 0.48–0.63; Iii=0%, p=0.841) and mortality (RR 0.88, 95% CI 0.lxxx–0.97; I2=0%, p=0.888).
This is the first report that has constitute a subtract of mortality associated with the use of subglottic secretion drainage. In add-on, subglottic secretion drainage is an effective measure to reduce VAP incidence, despite non improving the elapsing of mechanical ventilation and ICU and/or hospital length of stay.
Abstract
Subglottic secretion drainage is an constructive measure to reduce mortality and VAP incidence, despite not improving the duration of mechanical ventilation or length of stay in ICU and/or hospital. http://bit.ly/2PeJLR1
Introduction
Ventilator-associated pneumonia (VAP) is a hospital-acquired pneumonia developed in intubated patients receiving mechanical ventilation for ≥48 h [1]. VAP is amongst the highest incidence hospital-caused infections in intensive care units (ICU) affecting ane-tertiary of patients with mechanical ventilation and having an attributable bloodshed of four.half-dozen–13% [two, three]. The high incidence and mortality attributable to VAP are associated with increased resource utilisation burden generating a high economic toll to healthcare systems. Thus, price-effective interventions that minimise the incidence of this adverse result are needed [4].
The necessary use of the endotracheal tube is i of the chief risk factors for the development of VAP. It interferes with the normal protective upper airway reflexes, reduces constructive coughing, causes irritation of the respiratory mucosa, increases the corporeality of mucus and promotes microaspiration of contaminated oropharyngeal secretions [5]. This microaspiration is the chief mechanism for the entry of leaner into the lower airway [vi, 7], which could lead to VAP, depending on the quantity and virulence of aspirated bacteria and the patient's defense mechanisms [viii].
Subglottic secretion drainage (SSD) has been studied extensively as a strategy for VAP prevention in such a way that >20 randomised controlled trials (RCTs) and several meta-analyses take assessed the effectiveness of this technique to reduce incidence of VAP. Nevertheless, although several guidelines recommend its employ, the use of SSD is not widespread, probably due to the weakness of the quality of evidence [9–12].
For these reasons, the aim of this study was to synthesise the available prove providing an overview of systematic reviews about the effectiveness of SSD to reduce VAP, length of stay in ICU and/or hospital, duration of mechanical ventilation and mortality. Additionally, an updated meta-analysis was conducted, which aimed to provide updated bear witness about this topic.
Methods
This overview of systematic reviews and the updated meta-assay were registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42019123699). The updated meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [thirteen], and the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions [fourteen] were followed.
Data sources and search methods
An electronic search of the Cochrane Library, MEDLINE (via PubMed), Web of Science and Embase (via Scopus) was undertaken, from inception to July 17, 2019, to identify systematic reviews with meta-analysis and RCTs that aimed to appraise the effectiveness of SSD to prevent VAP.
The search strategy was "ventilator-associated pneumonia" AND ("subglottic secretion" OR "subglottic aspiration" OR "subglottic drainage" OR "subglottic suctioning" OR "endotracheal intubation" OR "endotracheal tube" OR "endotracheal cuff") AND ("meta-analysis" OR "systematic review" OR "randomised controlled trial"). There were no appointment or language restrictions. In addition, the reference listing of published full-text articles and systematic reviews were manually scanned for relevant studies (meta-analyses and RCTs).
Option criteria and data extraction
The inclusion criteria for the overview of systematic reviews with meta-analysis were 1) population: developed patients admitted to ICUs; 2) blazon of study: systematic reviews with meta-assay of RCTs; 3) type of intervention: use of endotracheal tubes that allow SSD for VAP prevention compared with the standard endotracheal tube or non-SSD control group; iv) primary outcome: VAP incidence; and five) secondary outcomes: ICU and/or infirmary mortality, duration of mechanical ventilation, ICU and/or hospital length of stay and time to VAP.
Additionally, the identified contained RCTs that aimed to assess the effectiveness of SSD to prevent VAP in adults admitted to ICUs were selected and reviewed for an updated meta-analysis. Studies in children or paediatric ICUs and studies with inconsistent or bereft data were excluded. Abstract publications were also excluded.
2 contained reviewers (DPP-C and AH-A) conducted both the selection of studies and data extraction. Duplicate studies and irrelevant titles were removed. Disagreements were solved by give-and-take, and if disagreement persisted, a tertiary reviewer solved the conflict (VM-V). Reviewers were non blinded to authors, journals or institutions.
Data from the included systematic reviews with meta-analysis were extracted through a standard data extraction form; the original studies were used when specific information were missing. The following data from each included systematic review were extracted: 1) first author'due south name; 2) twelvemonth of publication; 3) number of included RCTs and participants; 4) study aim; 5) eligibility criteria (details of the included participants and details of the intervention studied); 6) data for the risk ratio (RR) for dichotomous outcomes (VAP incidence and bloodshed) and mean differences for continuous outcomes (duration of mechanical ventilation, ICU and/or hospital length of stay and time-to-VAP); and 7) any additional methodological information of potential importance, such equally the assessment of methodological quality, hazard of bias, limitations and quality of prove.
Additionally, each RCT was reviewed for necessary data; when some data were not bachelor, each systematic review with meta-analysis in which that written report was included was also reviewed to acquire whatever missing data. The post-obit information were extracted from each included article: i) first writer's proper name; 2) yr of publication; 3) study name and study aim; four) participant characteristics (number, age); 5) intervention characteristics (SSD method, co-interventions in the intervention group, VAP prevention bundle); and 6) VAP incidence, ICU and/or hospital length of stay, elapsing of mechanical ventilation, time to VAP and mortality both in the command and intervention groups.
Quality assessment
Two authors (DPP-C and AH-A) independently rated the methodological quality and the quality of testify of each event of the systematic reviews with meta-assay, and the risk of bias of the RCTs included.
Overview of reviews
Methodological quality of included reviews
The Assessment of Multiple Systematic Reviews (AMSTAR-2) tool was used to appraise the methodological quality of each included review [xv]. This tool consists of 16 items in total with simple response categories. These items include, among others, the presence of a protocol, comprehensiveness of the literature search and assessment of the risk of bias of the individual studies included in the systematic review.
Quality of evidence
The Grading of Recommendations, Assessment, Development and Evaluations (Course) tool was used to assess the quality of the evidence related to the cardinal outcomes when the reviews did not provide a Course assessment [16]. This system uses the following criteria to assign a quality level to a torso of bear witness [fourteen]: 1) high (randomised trials or double-upgraded observational studies); 2) moderate (downgraded randomised trials or upgraded observational studies); 3) low (double-downgraded randomised trials or observational studies); 4) very depression (triple-downgraded randomised trials, downgraded observational studies or case series/case reports).
Additionally, some factors which can increase and/or subtract the quality of bear witness were considered: ane) limitations of the studies, such as the likelihood of bias (downgraded once if <75% of the included studies were at low risk of bias); 2) inconsistency including unexplained heterogeneity or inconsistency of results (downgraded once when the Itwo statistic was >fifty%); 3) indirectness, such as indirect population, intervention, command or outcomes; iv) imprecision manifested in wide confidence intervals; and 5) high probability of publication bias, which was downgraded once if at that place was evidence or high likelihood of publication bias [14, 17, 18].
The GRADEpro GDT software (www.gradepro.org) was used to perform the "summary of findings" tables from each systematic review included.
Updated meta-analysis
Risk of bias assessment
Hazard of bias was evaluated according to the PRISMA recommendations [nineteen]. The methodological quality of studies was assessed using the Cochrane Collaboration's tool for assessing take chances of bias [20]. This tool evaluates the hazard of bias according to six domains: pick bias (random sequence generation and allotment concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete issue data), reporting bias (selective reporting) and other biases. In this quality assessment tool, each domain is considered as low risk, unclear risk or high chance of bias.
Data synthesis
Overview of reviews
For this section, data from the included systematic reviews with meta-analysis were extracted and presented in an "overview of reviews" table.
Appropriate effect sizes were used, presenting RR for VAP incidence and mortality, and mean differences for elapsing of mechanical ventilator, ICU and/or hospital length of stay and fourth dimension to VAP. When the systematic reviews with meta-analysis did not report the suitable effect size, the original information presented was used to calculate it.
Updated meta-analysis
Standardised mean differences (SMD) and 95% confidence intervals for duration of mechanical ventilation and ICU and/or hospital length of stay, and the RR for VAP incidence and mortality were calculated between groups (intervention versus control) in each written report and pooled using the Mantel–Haenszel stock-still-effects model [21] or the DerSimonian–Laird random-furnishings model [22] depending on heterogeneity (fixed-effects model for I2<50% and random-effects model for Itwo>l%).
Heterogeneity was assessed using the I2 statistic, and the following values were used for interpretation: low (0–xl%); moderate (30–60%); substantial (50–xc%) and considerable (75–100%); the respective p-values were as well considered [14]. Sensitivity analyses were conducted by deleting each report from the model, and the pooled analyses were recalculated without each report to appraise its influence on the overall SMD or RR. To test the presence of publication bias, a funnel plot and Egger'south test were used [23].
In addition, an exploratory analysis was performed to analyse whether the technique used to diagnose VAP (bronchoalveolar lavage or protected specimen brushed versus endotracheal aspiration) could influence the overall event size.
Statistical analyses were performed using STATA software (version 14; StataCorp, College Station, TX, USA).
Results
Details of the search screening procedure are presented in figure 1, and the reasons for excluding the 15 remaining total-text studies are shown in the supplementary material. Finally, 29 studies were included: nine systematic reviews with meta-analysis in the overview of reviews [24–32] and 20 RCTs in the updated meta-analysis [33–52].
- Download figure
- Open in new tab
- Download powerpoint
FIGURE 1
Literature search: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram. SRMA: systematic reviews with meta-assay; RCT: randomised controlled trial; SSD: subglottic secretion drainage.
Overview of reviews
Systematic reviews with meta-analysis characteristics
Supplementary table S1 shows the characteristics of the systematic reviews with meta-assay included. Nine systematic reviews with meta-analysis that investigated the use of SSD for VAP prevention were included. These systematic reviews with meta-analysis were published betwixt 2005 and 2018, and included 31 876 adults across 20 unique RCTs.
Two systematic reviews with meta-analysis excluded RCTs in which, in improver to using the SSD technique, other co-interventions were carried out in the experimental group [27, 28]. I systematic review with meta-analysis excluded RCTs in which the principal outcome was not VAP micro-organisms [32].
Outcome measures
An overview of the results of the included systematic reviews is provided in supplementary table S2. All included systematic reviews with meta-assay reported information concerning VAP incidence. The RR of the SSD intervention on the reduction of VAP incidence ranged from 0.52 (95% CI 0.43–0.64) to 0.59 (95% CI 0.48–0.75), showing a significant subtract in incidence in all included systematic reviews with meta-assay.
Four systematic reviews with meta-analysis reported the RR for overall bloodshed [24, 26, 28, 30], iii reported the RR for ICU and hospital mortality separately [25, 27, 29], and i did not study the RR for bloodshed [31]; nonetheless, no review constitute a significant upshot of SSD in reducing mortality.
The effect of SSD on the reduction of ICU and/or hospital length of stay was significant in 4 reviews [24, 28, 29, 31] ranging from 1.iv (95% CI −two.i–−0.08) to iv.27 (95% CI −vii.36–−1.eighteen) days fewer in the SSD group than in the non-SSD grouping.
The use of SSD shortened the duration of mechanical ventilation between 3.29 (95% CI −4.53–−2.05) and 1.08 (95% CI −2.04–−0.12) days, although some reviews did not find a pregnant reduction in the number of mechanical ventilation days [26, 27].
Additionally, five systematic reviews with meta-analysis [25, 27, 28, 30, 31] reported data for the fourth dimension-to-VAP outcome, showing that the SSD intervention delayed the appearance of VAP between 2.66 (95% CI 1.06–4.26) and 4.04 (95% CI two.6–5.47) days.
Quality cess
Only one review presented a rating for the certainty levels of show and the strength of recommendations using the Course tool [25].
The methodological quality and the quality of the bear witness of the remaining included systematic reviews with meta-analysis were assessed. The quality of evidence for each issue in each systematic review with meta-assay is shown in supplementary table S3. The master limitations decreasing the level of prove were non reporting the I2 value to assess heterogeneity or the I2 value was >50%; not assessing publication bias; and not assessing the gamble of bias of the RCTs included or when <75% of included RCTs were reported every bit having a low gamble of bias.
The methodological quality evaluation applying the AMSTAR-2 tool showed that the main critical domains were the absence of a protocol registered earlier outset the review (only one registered a previous protocol) [25]; the absence of justification for excluding studies (merely three studies provided a listing of excluded studies) [26, 28, 29]; and not assessing/reporting the gamble of bias [27, 28] or the publication bias of the included studies [28, 32] (supplementary tabular array S4).
Updated meta-analysis
Studies characteristics and participants
The 20 RCTs included were published between 1992 and 2017, and comprised 3684 adults receiving mechanical ventilation and admitted to ICUs [33–52]. The sample size of the studies ranged from 18 to 690 participants, including patients with neurological damage [35], cardiothoracic surgical patients [36, 43] and patients admitted to general and medical-surgical ICUs (supplementary table S5).
Pooled estimates, sensitivity analysis, publication bias
VAP incidence
All RCTs provided data for VAP incidence; SSD significantly reduced VAP incidence (RR=0.56, 95% CI 0.48–0.63; Iii=0%, p=0.841) (figure 2). In the sensitivity assay, when each study was removed, the results remained consistent beyond all exclusions.
Secondary outcomes
A significant departure was detected between the SSD intervention and non-SSD in mortality (RR 0.88, 95% CI 0.eighty–0.97; Iii=0%, p=0.888) (figure 3). Notwithstanding, there was no association found between the use of the SSD technique and the subtract in ICU length of stay (SMD −0.12, 95% CI −0.26–0.03; I2=67.4%, p=0.002), hospital length of stay (SMD −0.06, 95% CI −0.fourteen–0.03; I2=10.vi%, p=0.348) and elapsing of mechanical ventilation (SMD −0.07, 95% CI −0.20–0.07; I2=62.4%, p=0.003) (supplementary effigy S1).
Time-to-VAP outcomes were not pooled because the only two new RCTs included in the updated meta-assay did not report information regarding this consequence, which does not change the data presented in the previously published meta-analysis [25].
For the bloodshed outcome, the sensitivity analysis showed pregnant reductions after excluding the studies by Fiveallés et al. [51] and Liu et al. [45].
For all outcomes, both visual inspection of the funnel plot and Egger's test did not testify substantial disproportion, indicating the absenteeism of publication bias.
The exploratory analysis performed to analyse whether the technique used to diagnose VAP (bronchoalveolar lavage or protected specimen brushed versus endotracheal aspiration) could influence the overall effect size showed that the use of SSD conveys a significant reduction in VAP in both subgroups, irrespective of the technique used to diagnose VAP.
Risk of bias assessment
Gamble of bias is summarised in supplementary figure S2. 13 studies had a low risk of bias in the random sequence generation domain; withal, just four had a depression hazard of bias in the allocation concealment item. 8 studies had a low risk of bias in the blinding of personnel and event assessment, while four studies had a low risk of bias in all domains [33, 34, 37, twoscore].
Give-and-take
This work comprises an overview of nine systematic reviews with meta-analysis and an updated meta-analysis examining the effectiveness of SSD in reducing VAP incidence, ICU and/or infirmary length of stay, duration of mechanical ventilation and mortality. SSD significantly reduced the incidence of VAP in all systematic reviews with meta-analysis and in the updated meta-assay, but the results were not statistically meaning for ICU and/or infirmary length of stay and duration of mechanical ventilation. Nevertheless, contradictory results were observed regarding bloodshed between the overview of reviews and the updated meta-analysis results, with a significant trend towards less bloodshed existence found in the updated meta-assay.
1 potential reason for such discordance in mortality could exist a lack of power to detect meaning effects, every bit Caroff et al. pointed out [26, 53]. Interestingly, as sample size increases in our updated meta-analysis (3200 versus 3684), a trend towards a decrease in mortality is seen, reaching statistical significance, which may suggest a true effect. Independently, a big epidemiological study concluded that even if the strategies for VAP prevention did not decrease mortality, which could be influenced by many factors or confounders, they provided advantages to patients, their families and the healthcare arrangement [54].
Several guidelines recommend the utilize of SSD equally part of a care bundle to forbid VAP [10–12, 55, 56]; however, this preventive measure is not widely used. Since those patients undergoing prolonged mechanical ventilation seem to benefit more than from SSD, i reason for underusing SSD (along with a college economic cost) could be the absence of factors assuasive authentic prediction of prolonged mechanical ventilation. Moreover, it has been suggested that re-intubation with SSD may represent a risk cistron for VAP [57, 58]. Regarding the toll of SSD, several toll-effectiveness studies have compared costs associated with the use of SSD endotracheal tubes versus standard endotracheal tubes amongst intubated patients [59–61]. Although specialised endotracheal tubes that permit SSD accept a cost approximately seven times greater than conventional endotracheal tubes, all cost-effectiveness studies concluded that the SSD is a price-effectiveness VAP preventive strategy [60, 61]. Another reason for the underuse of SSD as a VAP preventive strategy could exist that improvements in other outcomes are non observed aslope the decreased VAP rates.
Our updated meta-analysis did non observe a significant reduction in the duration of mechanical ventilation associated to the utilise of SSD. A review addressing this issue [53] concluded that because the use of SSD reduces the mortality take a chance associated to VAP in 10% (an estimated mortality rate of 5–nine% would be reduced by 0.five–0.9%), a sample size of tens of thousands would exist necessary to reach statistical significance and thus demonstrate that SSD could reduce ICU and infirmary mortality. Co-ordinate to this, although our updated meta-assay provides a greater sample than those previously published, it may also be underpowered to obtain statistical significance. In addition, heterogeneity in the duration of mechanical ventilation is far greater than in bloodshed, thus implying that a larger sample size is needed to have enough statistical power. Nevertheless, consequent with the results found regarding mortality, the meta-analysis shows a trend towards a reduction in the duration of mechanical ventilation (along with ICU and/or hospital length of stay). In addition, other confounders such as unlike VAP preventive measures, treatments and patient's characteristics (comorbidities, age, principal pathology, etc.) could influence this relationship.
In general, the capacity of SSD to reduce ICU and/or length of stay based on quality evidence is considered scarce. Some reviews have showed a meaning decrease of ICU length of stay in the SSD group; nevertheless, these reviews had low levels of quality of evidence, which limits the reliability of the results [28–31]. In our updated meta-assay, neither ICU nor hospital length of stay showed any improvement associated to the use of SSD.
Time to VAP was significantly increased in the SSD group in some systematic reviews; nevertheless, again, the Form quality of evidence was poor (low or very low for four studies [27, 28, 30, 31] and moderate for one [25]).
Our work has several limitations. First, the quality of testify was just reported in two out of 9 systematic reviews with meta-analysis. Second, the methodological quality of the systematic reviews with meta-analysis varied, ranging from critically depression to high, although the majority had a low to moderate quality. Third, there was a wide heterogeneity in the population and in the blazon of ICUs included in the RCTs. Fourth, different diagnostic VAP criteria, such as quantitative cultures, bronchoalveolar lavage or clinical and radiologic criteria were used in the RCTs included. This could have a negative influence in terms of heterogeneity in our meta-analysis. Fifth, the utilize of SSD along with other VAP preventive measures did not allow us to distinguish the individual effect of SSD to prevent VAP. Moreover, these VAP bundles and/or co-interventions were different in the included studies, potentially representing a source of heterogeneity. 6th, although a subgroup analysis past SSD techniques could be viable in this meta-analysis, information technology was disregarded because recent meta-analyses [25, 62] did not study whatsoever differences between continuous and intermittent SSD to forestall VAP. Finally, due to the nature of the intervention, information technology could not exist blinded for health staff, so simply some RCTs were partially blinded.
The major strength of the nowadays study is its development according to the Cochrane methodology and the PRISMA guidelines. Additionally, we provided a Class level of evidence for all included outcomes when the systematic reviews with meta-analysis did not provide a Course assessment. Moreover, a protocol of this overview was previously registered in PROSPERO. Finally, an updated meta-assay including the most contempo RCTs was performed, mainly yielding similar results to those obtained in previous meta-assay simply also finding a significant reduction in mortality associated to the apply of SSD practice.
Determination
This overview provides an updated synthesis of bachelor evidence most the use of SSD to prevent VAP, which found SSD to exist an effective measure to prevent VAP and reduce bloodshed. However, since improvements in other outcomes such as the duration of mechanical ventilation and ICU and/or infirmary length of stay were non observed alongside VAP rate improvements, further high-quality studies are necessary to elucidate the potential contribution of SSD in medical care.
Supplementary material
Footnotes
-
Since publication of this article, information technology has been found that at that place is an error in the analysis presented in figure 3. This is indicated in the correction notice published in volume 31, outcome 163 of the European Respiratory Review, and fully clarified by the authors in their correspondence to the editor published in the same issue (https://doi.org/10.1183/16000617.0013-2022)
-
This commodity has supplementary fabric available from err.ersjournals.com
-
Provenance: Submitted article, peer reviewed
-
Conflict of interest: D.P Pozuelo-Carracosa has nada to disclose.
-
Disharmonize of interest: A. Herráiz-Adillo has nothing to disembalm.
-
Conflict of interest: C. Alvarez-Bueno has null to disclose.
-
Disharmonize of interest: J.Grand. Añón has zip to disclose.
-
Conflict of interest: V. Martínez-Vizcaíno has nothing to disclose.
-
Disharmonize of involvement: I. Cavero-Redondo has naught to disclose.
- Received Baronial 15, 2019.
- Accepted October 21, 2019.
- Copyright ©ERS 2020.
References
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
Source: https://err.ersjournals.com/content/29/155/190107
Post a Comment for "Subgloticc Secretion Drainage for Prevention of Vap Systematic Review"